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doi:10.1016/j.ejvsextra.2011.06.005Abstract Introduction: Mesenteric vein stenosis and thrombosis are rare conditions, without
a definite treatment strategy.
Report: A 46 year-old man underwent pancreatic resection with a polytetrafluoroethylene
(PTFE) graft vascular reconstruction; he subsequently developed anastomotic mesenteric vein
stenosis, which was treated with transhepatic venoplasty and stenting. Three months later, he
suffered an in-stent thrombosis, after a reduction in heparin dosage. The thrombosis was
successfully managed, after a failed systemic thrombolysis, with a direct thrombolysis via
transjugular approach. At 10 months’ follow-up, the stent was still patent.
Conclusion: Mesenteric vein stenting is effective on PTFE grafts, but appropriate anticoagula-
tion is helpful to avoid subsequent in-stent thrombosis.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Introduction
Mesenteric vein stenosis and thrombosis are rare condi-
tions, and there is no definite treatment strategy.1 Percu-
taneous endovascular treatment, such as transjugular
portosystemic shunt, direct and indirect thrombolysis,
stenting and mechanical thrombectomy, were described in
liver-transplant patients, while much less is known aboutjvs.2011.06.048.
mbre 15, 20123 Milano, Italy.
694.
l.com (G. Mauri).
r Vascular Surgery. Published bymanagement of these conditions in the non-transplant
population.2e5 Moreover, because vascular reconstruction
with polytetrafluoroethylene (PTFE) graft represents
a recent advance in pancreatic surgery, no literature exists
about endovascular treatment in these conditions.
Report
A 46-year-old male patient was admitted for worsening
ascitis 4 months after total pancreasectomy with PTFE graft
vascular reconstruction performed in a different country.
He was treated for locally advanced cephalo-pancreatic
adenocarcinoma with invasion of superior mesenteric vein.
He underwent a neo-adjuvant chemoradiation protocolElsevier Ltd. Open access under CC BY-NC-ND license.
e28 G. Mauri et al.with F-fluorouracil (5FU) c.i. and concurrent radiotherapy
(total dose 55 Gy). At surgery, superior mesenteric vein
resection and reconstruction with PTFE graft and dissection
of the superior mesenteric artery, encased from the
tumour, were done; intra-operative radiotherapy (19 Gy
isodose) was added. Histology showed vein invasion, pT3,
N17/56, M0, and the operation was judged R1.
There was no evidence of disease recurrence. Computed
tomography (CT) scan demonstrated two stenoses on
proximal and distal anastomosis. Percutaneous trans-
hepatic portography was performed and two stents were
placed: a 10  40 mm stent (Sentinol, Boston Scientific,
Natich, MA, USA) at the proximal edge and a 12  50 mm
stent (Wallstent, Boston Scientific, Natich, MA, USA)
distally (Fig. 1). The ascitic fluid gradually resolved and the
patient was discharged 12 days later; lowemolecular-
weight Heparin (LMWH) 11 400 UI diem1 (Seledie, Glaxo
Allen S.p.A, Brentford, Middlesex, UK) was prescribed.
Three months later, as the patient required percutaneous
radiofrequency (RF) ablation for single focal hepatic
metastasis, his anticoagulation therapy was halved to
a prophylactic dose of 5700 UI diem1.
Ten days after the anticoagulation therapy was modi-
fied, he complained of recurrent ascitis: a new computed
tomography (CT) scan showed in-stent venous thrombosis.
A systemic thrombolysis with recombinant tissue-
plasminogen activator (rt-PA) (Actilyse, Boehringer Ingel-
heim, Ingelheim am Rhein, Germany) with a single bolus of
10 mg, followed by 90 mg in 2 h, was unsuccessful and
complicated by serious digestive haemorrhage. This latter
required repeated blood transfusions. It was decided to
perform mechanical aspiration thrombectomy by a 6F
catheter (Imager II, Boston Scientific, Natich, MA, USA) and
angioplasty by a 9 mm balloon (EverCross, EV3, Plymouth,
MN, USA) followed by direct thrombolysis through trans-
jugular intrahepatic approach. Using a straight 4F catheter
(Imager II, Boston Scientific, Natich, MA, USA) positioned in
superior mesenteric vein, rt-PA was administered with theFigure 1 (A) Percutaneous transhepatic angiography demonstra
(white arrow) anastomoses of the PTFE graft. (B) Angiography aft
distal stent) shows resolution of the stenosis.following regimen: single bolus of 15 mg followed by infu-
sion of 50 mg in 1 h and of 35 mg in 2 h. Unfractioned
heparin was given simultaneously to maintain prothrombin
time (PT) between 50 and 70 s. The procedure led to
restoration of regular superior mesenteric vein patency
(Fig. 2), and ascitic fluid resolved. The patient was then
discharged with Seleparin 11400 UI diem1 (Seleparina,
Italfarmaco S.p.A, Milan, Italy).
Treated with the appropriate dose of heparin, at 10-
month follow-up CT, the vessel was patent and the patient
did not experience any ascitis’ recurrence. The patient
died 15 days later owing to disease progression.Discussion
Some series report successful treatment of portal vein
stenosis by angioplasty in liver-transplant patients, but
much less is known in the non-transplant population.2
Transhepatic access to the portal system is generally
easier than transjugular access, but there are concerns
about a higher risk of peritoneal haemorrhage with that
approach. In the present case, anastomotic venoplasty and
stenting was successfully and safely performed by the
transhepatic route as far as the hepatic tract could be
closed by coil placement. Unfortunately, the decision to
reduce anticoagulation before an RF ablation for a hepatic
metastasis fostered a clinically relevant in-stent throm-
bosis, whose management was difficult until direct throm-
bolysis, performed via the transjugular approach to reduce
the chance of a further peritoneal bleeding. Actually, there
is no consensus on the optimal management strategy for an
occluded venous bypass graft. Systemic thrombolysis is less
invasive for the patient, and we sought to use it as first
therapeutic strategy.
Our experience shows that endovascular treatment may
be an effective option for post-surgical mesenteric vein
stenosis, but anticoagulation plays an important role totes stenosis at the level of proximal (black arrow) and distal
er stent placement (black arrow proximal stent, white arrow
Figure 2 (A) Contrast injection in SMV (arrow) demonstrates complete vessel occlusion. (B) angiography after aspiration
thrombectomy and angioplasty shows residual thrombus (arrow). (C) Complete resolution and calibre restoration after direct
thrombolysis with rt-PA.
Superior Mesenteric Vein Stenosis and Thrombosis e29avoid in-stent thrombosis: in our case, a thrombosis
occurred as soon as we halved the anticoagulation regimen.
To the best of our knowledge, no case of percutaneous
endovascular treatment of mesenteric vein stenosis or
thrombosis after pancreatic surgery with PTFE graft
vascular reconstruction has been reported.
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